Nā huahana

ʻO nā ala e mālama ai i ka T2DM, kahi maʻi i hōʻike ʻia e ka hemahema ʻelua o ka hana ʻana o ka islet cell dysfunction a me ka insulin resistance, nā mea hana e hoʻonui ai i ka huna ʻana o ka insulin e ka pancreas (secretagogues), nā mea hana e hoʻonui ai i ka naʻau o nā kino i hoʻopaʻa ʻia i ka insulin (sensitizers), a ʻO Liraglutide, ka GLP-1 receptor agonist e hōʻea i ka mākeke, loaʻa iā ia kahi 97% homology i GLP-1 me ʻelua mau hoʻololi amino acid a me ka hoʻohui ʻana o kahi kaulahao ʻaoʻao momona.ʻO ke kikoʻī, ua hoʻololi ʻia ka lysine ma ke kūlana 34 me kahi arginine, a ua hoʻololi ʻia ka lysine ma ke kūlana 26 me kahi kaulahao acyl C16 ma o kahi spacer glutamoyl.Loaʻa ka Liraglutide i kona kū'ē i ka DPP-4 degradation mai kona makemake e hana i nā micelles a hoʻopaʻa i ka albumin.ʻAʻole i like me kāna exenatide mua, e koi ana i ʻelua mau inikini subcutaneous i kēlā me kēia lā ma mua o ka ʻai mua a me ka hope o ka lā, ua ʻae ʻia ka liraglutide ma ke ʻano he regimen mālama hoʻokahi i kēlā me kēia lā a hiki ke hoʻohana pū ʻia me ka metformin a i ʻole sulfonylurea i nā mea maʻi me ka lawa ʻole o ka mana glycemic me kekahi. monotherapy a i ʻole ka hui ʻana i nā lāʻau ʻelua.Ua ʻae ʻia i ka hui pū ʻana me ka lāʻau lua o ka metformin a me kahi thiazolidinedione i nā mea maʻi me ka lawa ʻole o ka mana glycemic.Ua hōʻike ʻo Liraglutide i ka mana paʻa o 61 pM (EC50= 55 pM no GLP-1) no ka mea hoʻokipa GLP-1 kanaka cloned.